Genelux reports 16.7-month PFS in phase 1b/2 Olvi-Vec trial case study for platinum-relapsed SCLC

PUBT · 1d ago
Genelux reports 16.7-month PFS in phase 1b/2 Olvi-Vec trial case study for platinum-relapsed SCLC
  • Genelux flagged a peer-reviewed case report from its OLVI-VEC-202-SCLC study in platinum-relapsed small cell lung cancer.
  • Results were previously reported in part, then published in Frontiers in Oncology on Sept. 9, 2026.
  • The patient showed a deep, durable tumor response following intravenous Olvi-Vec, then platinum chemotherapy re-challenge.
  • Outcome exceeded the patient’s earlier first-line platinum-based treatment, supporting Olvi-Vec’s potential to restore chemotherapy sensitivity.
  • Enrollment continues in systemic Olvi-Vec lung cancer trials; additional dose-finding updates are expected later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609091601PRIMZONEFULLFEED9824002) on September 09, 2026, and is solely responsible for the information contained therein.